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Unbalanced epigenetic regulation is thought to contribute to the progression of several
neurodegenerative diseases, including Huntington’s disease (HD), a genetic disorder
considered as a paradigm of epigenetic dysregulation. In this review, we attempt
to address open questions regarding the role of epigenetic changes in HD, in the
light of recent advances in neuroepigenetics. We particularly discuss studies using
genome-wide scale approaches that provide insights into the relationship between
epigenetic regulations, gene expression and neuronal activity in normal and diseased
neurons, including HD neurons. We propose that cell-type specific techniques and 3D-
based methods will advance knowledge of epigenome in the context of brain region
vulnerability in neurodegenerative diseases. A better understanding of the mechanisms
underlying epigenetic changes and of their consequences in neurodegenerative
diseases is required to design therapeutic strategies more effective than current
strategies based on histone deacetylase (HDAC) inhibitors. Researches in HD may play
a driving role in this process.
Keywords: neuroepigenetics, Huntington’s disease, epigenomics, transcriptomics, neuronal activity, HDAC
inhibitors, neurodegenerative diseases
INTRODUCTION
Huntington’s disease (HD) is a genetic disease affecting preferentially medium spiny neurons
(MSN) of the striatum. Increasing numbers of studies provide evidence for altered epigenetic
regulations in HD. Here, after a summary of general epigenetic mechanisms in neurons, we review
the state-of-the-art of epigenetic changes in HD. We discuss the mechanisms underlying these
changes and their consequences, particularly on expression of neuronal identity genes. Current
challenges to improve our understanding of the role of epigenetic mechanisms in HD are discussed,
including the development of new technologies to profile neuronal epigenomes at single-cell or
cell-type specific levels. Epigenetic modifications represent promising therapeutics. We discuss
the need of identifying new epigenetic targets for therapy, representing alternatives to histone
deacetylase (HDAC) inhibitors.
Epigenetic Mechanisms: General Rules
The current definition of epigenetics relates to “the study of phenomena and mechanisms that
cause chromosome-bound, heritable changes to gene expression that are not dependent on
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changes to DNA sequence” (Deans and Maggert, 2015).
Epigenetic mechanisms actually regulate several DNA/RNA-
mediated processes, including transcription, DNA repair and
DNA replication, through modulation of the structure of
chromatin, a macromolecular complex of DNA, RNA and
proteins such as histones. Two major epigenetic mechanisms
influence chromatin structure: histone modifications and DNA
methylation (Allis and Jenuwein, 2016) (Figure 1).
In the nucleus, DNA is wrapped around core particles of
chromatin, the nucleosomes, which are formed of octamers
of histones, including H2A, H2B, H3, and H4. Histones are
subject to various post-translational modifications (PTM) such
as acetylation, methylation, phosphorylation and ubiquitylation.
These histone modifications modulate the degree of compaction
of nucleosomes, thereby affecting chromatin accessibility to
various factors, particularly transcriptional regulators. (Jenuwein
and Allis, 2001; Borrelli et al., 2008; Wang and Jin, 2010;
Tsompana and Buck, 2014; Xu et al., 2014). Importantly, histone
residues can be modified in a combinatorial, reversible,
and targeted manner (Figure 1). For instance, histone
acetyltransferases (HAT) and HDAC are involved in acetylation
and deacetylation of specific histone residues, respectively
(Figure 1). Similarly, methylases and demethylases regulate the
addition and removal of methyl groups on histone residues
(Figure 1). The combinatorial, reversible and targeted nature
of histone modifications is the basis of the so-called ‘histone
code’. It permits to achieve specificity in the outcome, through
the action of proteins interpreting the code (e.g., “readers”)
(Jenuwein and Allis, 2001; Bannister and Kouzarides, 2011; Jones
et al., 2016). One major outcome is transcription. General rules
of the “transcriptional” histone code are relatively well defined.
For instance, histone acetylation, whatever the histone or the
residue modified, promotes relaxed chromatin and is associated
with transcriptional activation, whereas histone methylation,
depending on the specific residue that is modified, can lead to
transcriptional repression or activation. For instance, H3K9
methylation is associated with transcription repression, whereas
H3K4 methylation correlates with transcription activation.
Moreover, the genome comprises different regulatory regions,
including promoters and enhancers (i.e., regulatory regions
distal to promoters) playing specific roles in transcriptional
regulation. These regions display specific histone modifications.
For instance, promoters and enhancers of active genes are
enriched in trimethylated H3K4 (H3K4me3) and in acetylated
H3K27 (H3K27ac) respectively, further illustrating the targeting
precision permitted by the histone code.
DNA methylation, another important epigenetic mechanism,
consists in adding a methyl group to cytosines by DNA
methyltransferases (DNMT), particularly at C5 position of
cytosine in cytosine-guanine dinucleotide sequences (CpG),
creating 5-methylcytosine (5-mC). DNMT1 is implicated in the
maintenance of methylation patterns during DNA replication. In
contrast, DNMT3a and DNMT3b have been associated with de
novo DNA methylation (Jeltsch, 2006; Feng et al., 2010). Though
DNA methylation was long considered as a stable process, it
is now clear that post-mitotic cells can undergo active DNA
demethylation, through a mechanism implicating TET proteins
(Pastor et al., 2013). TET proteins induce hydroxylation of 5-mC
(leading to 5-hmc) and are further involved in their oxidation.
Oxidized 5-hmC are then processed by DNA repair mechanisms
and converted back to their unmethylated state (Guo et al., 2011;
Feng et al., 2015). 5-hmC is particularly extended in neurons,
suggesting that regulation of DNA methylation is highly dynamic
in these cells (Song et al., 2011; Szulwach et al., 2011). 5-mC
are bound by several classes of methyl-binding proteins (such as
MeCP2), which associate with other protein partners, including
HDAC, forming co-repressor complexes (Urdinguio et al., 2009;
Du et al., 2015). DNA methylation at gene promoters, generally
enriched in CpG sites and forming so-called CpG islands, is an
important mechanism involved in gene repression (Deaton and
Bird, 2011) (Figure 1).
The collection of epigenetic modifications (e.g., the
epigenome) can be assessed at genome-wide scale, using
next generation sequencing-based techniques such as chromatin-
immunoprecipitation-sequencing (ChIP-seq). Generation and
integration of epigenomic data with transcriptomic and/or
functional data to fully decode epigenomes at cell-type specific
level is a major current challenge that requires the development
of new techniques and analysis methods (Marconett et al., 2013;
Shin et al., 2014). In particular, methods to process low cell
numbers/single-cell need to be developed as well as powerful
bioinformatics tools (Bock et al., 2016).
Neuroepigenetics: Why are Neurons Specific?
Epigenetic mechanisms, interfacing individual genomes
with environmental factors, are essential to the regulation
of fundamental biological processes. Historically, epigenetic
mechanisms have been primarily explored in the context
of development, including cellular differentiation and the
establishment of stable cellular identity (Holliday, 2006; Roth
and Sweatt, 2011; Boland et al., 2014). In fact, cell state transitions
during development require massive epigenetic changes, whose
stabilization enables the maintenance of cell-type specific
identity. The mechanisms involve the establishment of defined
transcriptional programs. As a result, the epigenome is a
gatekeeper of cell-type specific identity. However, this view
of stable epigenetics has been challenged, due to evidence
showing that massive and dynamic epigenetic changes can be
implicated in the regulation of cellular activity. Such “plasticity”
of epigenetic regulations is particularly critical to neuronal
cell activity; hence the concept of neuroepigenetics (Borrelli
et al., 2008; Riccio, 2010; Sweatt, 2013; Deans and Maggert,
2015).
Neuronal excitability is one major property of neuronal cells.
In response to environmental experience, including learning,
drug exposure, psychological and physical stress environmental
signals, neurons undergo reversible transitions from resting to
active (or excited) states, which influence synaptic plasticity
and promote adaptive behavior, such as learning and memory
(Sultan and Day, 2011; Sweatt, 2016). These processes are highly
dynamic, and can also be long-lasting. Increasing evidence
indicates that epigenetic mechanisms regulate the transition from
resting to active neuronal state (Korzus, 2010; Landgrave-Gomez
et al., 2015; Meadows et al., 2016).
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FIGURE 1 | Epigenetic regulations are dynamic. Chromosomal DNA is wrapped around histone octamers (comprising dimers of H2A, H2B, H3, H4), forming
nucleosomes, the core unit of chromatin. Protruding N-terminus histone tails can undergo post-translational modifications (PTM) that influence chromatin state (e.g.,
relaxed vs. compact state) Epigenetic writers add PTM on histone tail residues. For example, histone acetyltransferases (HAT) add acetyl- (Ac) groups, and histone
methyltransferases (HMT) add methyl- (Me) groups. In a dynamic manner, these marks are removed by epigenetic erasers, such as histone deacetylases (HDAC)
and lysine demethylases (KDM), removing, respectively, Ac- and Me-groups. DNA methylation at cytosines, particularly at CpG dinucleotides, is performed by DNA
methyltransferases (DNMT). DNA demethylation involves hydroxylation and oxydation of methylated cytosines by Tet proteins (Tet), which are then repaired by DNA
repair mechanisms, including base excision repair (BER).
Learning and memory processes are associated with synaptic
plasticity, leading to the rapid formation of new synapses,
which can be strengthened or lost over time. Synaptic plasticity
correlates with dynamic changes at the level of histone
modifications. Specifically, changes in acetylation of histones,
including H3 and H4 have been associated with early formation
of new synapses (Federman et al., 2009; Chatterjee et al.,
2013; Graff and Tsai, 2013; Peixoto and Abel, 2013; Benito
et al., 2015). Moreover, neuronal activity can be associated
with memory storage and consolidation, which may involve
long-term remodeling of neuronal networks at system levels.
Epigenetic regulations have also been implicated in these
processes. Upon learning paradigms, the chromatin in brain
tissues implicated in memory formation and/or consolidation,
such as the hippocampus and the cortex, undergoes extensive
modifications, including increased histone acetylation and DNA
methylation changes (Day and Sweatt, 2011; Bousiges et al., 2013;
Zovkic et al., 2013; Halder et al., 2016). DNA methylation and
histone modifications both control memory processes, through
transcriptional effects that comprise the activation of synaptic
plasticity genes, including immediate early genes (IEGs) like Fos,
Egr1, or Arc (Minatohara et al., 2015; Thakurela et al., 2015).
Remarkably, these transcriptional effects that are experience-
driven and epigenetically regulated can be long lasting. Activation
of specific signaling pathways, such as the cAMP/CREB/CREB-
binding protein (CBP) pathway, is involved in the coupling
between epigenetic and transcriptional responses, promoting
the recruitment of protein complexes at target genes, which
induces chromatin remodeling and drive transcription (Cedar
and Bergman, 2009; Tie et al., 2014; Alberini and Kandel, 2015;
Ortega-Martinez, 2015).
However, although tight coupling between neuronal-activity-
regulated epigenetic and transcriptional changes remains a
favored hypothesis, recent data, integrating epigenomic, and
transcriptomic data suggest that the link between both events
may not be as clear as anticipated (Lopez-Atalaya and Barco,
2014; Liu et al., 2015; Valor, 2015b). Recently, contextual fear
conditioning in mice was used as a learning paradigm to
examine the spatiotemporal correlation between epigenetic and
transcriptional modifications in neurons (Halder et al., 2016).
Specifically, DNA methylation and seven histone modifications
were assessed at a genome-wide scale using hippocampal and
cortical neurons of mice that were subjected to contextual fear
conditioning. To specify the timing of epigenetic changes in
these tissues, analyses were performed at different time points
with respect to contextual fear conditioning, associated with
different memory processes, including memory formation and
consolidation. Transcriptomic analyses were also performed
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on the same tissues. Generally, histone modifications were
extensively modulated during memory formation, and these
widespread changes weakly correlated with gene-selective
transcriptional changes. In contrast, DNA methylation changes
were rather locus-specific and correlated with transcriptional
changes, including splicing events (Lev Maor et al., 2015;
Halder et al., 2016). Thus, the coupling between epigenetic and
transcriptional changes may depend on chromatin modifications.
Additional studies are required to specify causal relationship
between the two events. Other neuronal cells/tissues and
experimental paradigms may be used, which would permit to
investigate the interplay between epigenetics and transcription
in brain cells/tissues associated with additional brain functions,
including other cognitive functions, motor functions and
functions linked to emotion and motivation regulation.
Thus, it appears that epigenetic mechanisms in neurons not
only control their identity, like in other cell types, but also
regulate neuronal activation, including the ability to undergo
dynamic plasticity in response to environmental signals. Then,
the question arising is what is going on in pathological
situations, when neuronal function is impaired? Does it result
from altered activation capacity of affected neurons or from a
loss of neuronal identity? Are impaired epigenetic regulations
implicated in pathological processes? These questions are
particularly relevant to neurodegenerative diseases where specific
neuronal populations (or identities) are preferentially affected.
In the following sections, we have chosen to focus on one such
disease, HD, playing a pioneering role in the understanding of
the epigenetic regulation mechanisms in brain diseases.
EPIGENETICS IN HD
Huntington’s disease is a neurodegenerative disease caused by
an unstable expanded CAG repeats (>35–39 repeats) in the
Huntingtin gene (HTT), which results in the production of
mutant protein (mHtt) with a toxic polyglutamine (polyQ)
tract (Landles and Bates, 2004). HD is characterized by
specific symptoms, including motor impairment (e.g., chorea,
bradykinesia, gait abnormalities, dystonia), cognitive deficits
(motor skill learning deficits, planning, and attention troubles)
and psychiatric alterations (depression, mania, apathy, suicide),
usually appearing at adulthood (see as review, Roos, 2010).
Since polyQ expansion toxicity is correlated with repeat size,
HD patients with longer CAG expansions are more severely
affected, showing earlier onset of symptoms and faster pathology
progression. HD is characterized by a preferential and primary
degeneration of two structures of the basal ganglia: the caudate
nucleus and the putamen that form the neostriatum. However,
additional brain regions, particularly the cortex, degenerate as
the pathology progresses (Rosas et al., 2008). Remarkably, in HD
striatum, selective neuronal populations, the GABAergic MSN,
are more particularly vulnerable, whereas the large cholinergic
interneurons, the medium size GABAergic interneurons and glial
cells appear spared (Ferrante et al., 1987a,b; Cicchetti et al., 1996).
From a biochemical point of view, polyQ-Htt presents a high
propensity to misfold and aggregate, which leads to the formation
of nuclear inclusions, particularly in neurons (DiFiglia et al.,
1997; Li L. et al., 2016). These aggregates, a disease hallmark,
recruit a number of proteins, including transcriptional regulators
(Steffan et al., 2000; Arrasate and Finkbeiner, 2012).
A long period of neuronal dysfunction precedes the death of
neurons sensitive to the HD mutation. Several cellular processes
are believed to contribute to neuronal dysfunction, including Htt
cleavage and aggregation, abnormal protein-protein interactions,
dysfunctional calcium signaling, abnormal axonal transport,
impaired energy metabolism, dysregulation of neuronal activity,
and altered transcription (see as reviews Landles and Bates, 2004;
Zuccato et al., 2010; Labbadia and Morimoto, 2013; Saudou and
Humbert, 2016).
The “Neuronal” Signature of the HD
Transcriptome
Transcriptional dysregulation plays a central role in HD
pathogenesis (Seredenina and Luthi-Carter, 2012). Major
transcriptional changes have been reported in the brains of HD
patients (Hodges et al., 2006). This is also observed in HD mouse
models, including transgenic and knock-in mice (Luthi-Carter
et al., 2000; Luthi-Carter et al., 2002; Zucker et al., 2005; Roze
et al., 2008). Transcriptomic studies using mice showed that
transcriptional changes are progressive, CAG repeat-length-
dependent and most extended in the striatum (Desplats et al.,
2006; Kuhn et al., 2007; Becanovic et al., 2010; Langfelder
et al., 2016). In the striatum of HD models, transcriptional
changes occur in both directions: many genes are down- and
up-regulated (Seredenina and Luthi-Carter, 2012; Francelle et al.,
2014). Remarkably, down-regulated genes display a neuronal
signature, since decreased genes in HD striatum are enriched in
genes that define striatal neuron identity and function, such as
Darpp32, Rgs9, Drd1 or Drd2 (Hodges et al., 2006; Kuhn et al.,
2007; Vashishtha et al., 2013; Achour et al., 2015; Langfelder
et al., 2016). In the other affected brain regions such as the cortex,
fewer genes are down-regulated. However, they also present a
neuronal signature, reflecting tissue identity (Vashishtha et al.,
2013; Langfelder et al., 2016).
Interestingly, a recent study using RNAseq revealed a
developmental signature associated with differentially expressed
genes in post-mortem prefrontal cortex of HD patients.
Specifically, Hox genes and additional homeobox genes were
re-expressed in HD brains, suggesting that the transcriptome
of HD neurons resemble that of immature neurons (Labadorf
et al., 2015). Thus, these results support the view that the
transcriptional program involved in the maintenance of neuronal
identity is impaired in HD neurons. Up-regulated genes in the
striatum or cortex of HD patients were also enriched in biological
processes linked to inflammation (Hodges et al., 2006; Labadorf
et al., 2015). However, up-regulation of immune response genes
is not that clear in mouse models (Achour et al., 2015; Langfelder
et al., 2016). Thus, down- and up-regulated genes in HD brain
tissues display distinct functional signatures, suggesting that
different mechanisms may operate.
The mechanisms underlying mutant Htt-induced trans-
criptional effects are unclear. However, they are thought to
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involve both altered regulation of transcription regulators and
histone-modifying enzymes.
HDACi in HD: What are the Targets?
The hypothesis of an epigenetic origin of transcriptional
dysregulation in HD, particularly implicating histone acetylation,
has received increasing support over the years (Jaenisch and
Bird, 2003; Lee et al., 2013; Glajch and Sadri-Vakili, 2015). The
assumption that altered histone acetylation might contribute to
HD was made in the early 2000s, when it was found that the
HAT CREB-binding protein CBP is recruited into aggregates
of mutant Htt, and that HDAC inhibitors (HDACi) improve
phenotypes of drosophila and mouse models of HD (Nucifora
et al., 2001; Steffan et al., 2001; Kazantsev et al., 2002). As a
result, epigenetic strategies using HDACi to increase histone
acetylation have been early considered for HD. Several preclinical
studies have been performed using broad-spectrum HDACi
(e.g., suberoxylanilide hydroxamic acid (SAHA), Trichostatin A
(TSA), phenylbutyrate, sodium butyrate (NaB)] that target non-
selectively HDAC of class I and II (Ferrante et al., 2003; Hockly
et al., 2003; Gardian et al., 2005; Sadri-Vakili et al., 2007; Sharma
and Taliyan, 2015b).
Histone deacetylase inhibitors improve some phenotypes
of HD mice, including neuropathology and motor function.
However, it is unclear whether beneficial effects require
increased histone acetylation. Instead, studies suggest that the
mechanism may involve acetylation of non-histone proteins.
In support to this view, inactivation of a target of SAHA,
Hdac 4, ameliorates neurodegeneration in HD mice through
an apparently, transcription-independent mechanism, acting
on mutant Htt aggregation process (Mielcarek et al., 2011).
Non-histone-mediated beneficial effects of HDACi have also
been documented in models of Parkinson disease (PD; Godena
et al., 2014), suggesting common mechanisms between several
neurodegenerative diseases.
New compounds have been developed in an attempt to
generate more selective HDACi and with less toxic side
effects (Herman et al., 2006; Thomas et al., 2008). The
compound HDACi 4b, which was reported to ameliorate disease
phenotype of HD mice, show high potency for inhibiting
HDAC1 and HDAC3 (Thomas et al., 2008; Jia et al., 2012).
However, physicochemical properties and metabolic profile of
this compound were found suboptimal for investigation of
HDAC inhibition in mice per oral administration (Beconi et al.,
2012). The effect of RGFP966, an HDAC3-selective inhibitor,
was recently investigated using HD mice (Jia et al., 2016). The
results suggest that the compound limits glial cell response,
diminishing markers of glial cell activation. Surprisingly however,
a heterozygous inactivation of the Hdac3 gene in HD mice
did not ameliorate disease-related phenotypes (Moumne et al.,
2012), suggesting that more than 50% knock-down of the Hdac3
gene might be needed to see a beneficial effect. More recently,
beneficial transgenerational effects have been reported using
HDACi 4b in HD mice (Jia et al., 2015). Thus, despite some
beneficial effects, the mode of action of HDACi in HD models
remains elusive and may not systematically implicate histone-
and transcription-dependent mechanisms.
It is still unclear whether expression of neuronal identity
genes in HD brain tissues is restored upon HDACi treatment
(Coppede, 2014; Wang et al., 2014; Sharma et al., 2015; Valor,
2015a). Clinical studies using HDACi are ongoing and the results
are awaited. So far, Phase II studies provide indication for safety
and tolerability of several compounds, including phenylbutyrate
(Hogarth et al., 2007; Westerberg et al., 2015).
But what exactly is the status of the HD epigenome? Is
acetylation the only histone modification impaired in HD affected
tissues, and to which extent? Are acetylated histone residues
all affected the same way by the HD mutation? Is DNA
methylation also impaired? Is the chromatin structure globally
altered and repressed or is it altered at specific genomic regions
or gene loci? What is the underlying mechanism? What are the
consequences of chromatin structures changes? Do they underlie
transcriptional changes? Addressing these questions is certainly
a prerequisite to the development of new epigenetic therapies
for HD.
HD Epigenome
Many studies have already been performed that attempt to
address these issues (Lee et al., 2013; Valor and Guiretti, 2014;
Glajch and Sadri-Vakili, 2015). It is expected that the use of
genome-scale approaches, which has remained so far rather
limited in the HD field, will improve our knowledge of HD
epigenome as well as provide insights into the mechanism
responsible for altered epigenetic regulation in HD.
Relationship between Epigenetic and Transcriptional
Changes in HD
Histone acetylation
Extensive changes in histone acetylation levels were observed
in cellular systems based on mutant Htt overexpression (Steffan
et al., 2001; Igarashi et al., 2003). However, global levels of H2B,
H3 and H4 acetylation appeared unchanged between brain tissues
of HD R6/2 and control mice (Hockly et al., 2003; Sadri-Vakili
et al., 2007). Studies using the striatum of HD mice further
suggested that decreased H3 acetylation occurs at selective
gene loci, particularly at promoters of down-regulated genes
such as Drd2, Penk1, Actb, or Grin1 (Sadri-Vakili et al., 2007).
Using chromatin immunoprecipitation paired with microarray
hybridization (ChIP-chip), McFarland et al. (2012) assessed
histone acetylation changes at genome-wide scale in the striatum
of HD R6/2 transgenic mice. H3K9 and H3K14 acetylations
(H3K9,14ac) and transcriptional changes between HD and WT
striatum were poorly correlated in the striatum of HD R6/2
mice, suggesting that variation in H3K9,14ac levels alone may
not be sufficient to account for gene expression changes in
HD mice. Valor et al. (2013) reached similar conclusions by
investigating changes in H3K9,14 ac and H4K12ac using a more
powerful method –ChIPseq- on hippocampus and cerebellum of
the HD transgenic N171-82Q mouse model (Figure 2). However,
whereas data obtained by McFarland et al. (2012) suggest broad
changes in histone acetylation in HD mouse striatum when
compared to WT striatum, the results reported by Valor et al.
(2013) indicate that changes are restricted to few loci. The absence
of bulk changes in histone acetylation is further supported by a
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FIGURE 2 | Histone modifications and DNA methylation changes in Huntington’s disease (HD) neurons. Genes in healthy neurons are enriched in
transcriptionally active histone modifications, including acetylation of histone H3 at lysine 27 (H3K27ac), H3K9ac, H4K12ac, trimethylation of H3K4 (H3K4me3).
Down-regulated genes in HD neurons show decreased levels of active histone modifications and increased levels of histone modifications associated with
transcriptionnally repressed chromatin, including H3K9me2, H3K27me3, and ubiquitylation of H2A (H2A ub), resulting in less relaxed chromatin and decreased
transcription. These events may be associated with increased DNA methylation at gene promoters.
study showing promoter deacetylation of H3 at specific loci in
HD models (Guiretti et al., 2016).
H3K27ac, a mark of active enhancers, was also selectively
decreased in the striatum of HD R6/1 mice (Achour et al.,
2015) (Figure 2). Integrating H3K27ac ChIPseq with RNA
polymerase II (RNAPII) ChIPseq and RNAseq data, Achour
et al. (2015) showed that H3K27ac and RNAPII are decreased
at regions enriched in down-regulated genes, providing evidence
for a strong correlation between decreased H3K27ac, decreased
RNAPII and gene down-regulation in HD mouse striatum.
Moreover, enhancer regions presenting reduced H3K27ac in HD
R6/1 striatum were enriched in super-enhancers, a category of
broad enhancers, regulating genes that define cell type-specific
identity and function (Figure 3). In fact, striatal super-enhancer
genes down-regulated in HD mouse striatum were enriched in
genes controlling neuronal activity, including neuronal plasticity
and transmission (Achour et al., 2015). Thus, the results suggest
that selective decrease in super-enhancer activity underlies HD
neuronal transcriptomic signature (e.g., down-regulation of
genes that define neuronal identity and function, referred to as
neuronal identity genes thereafter). This supports an epigenetic
origin of gene down-regulation in HD.
Other histone modifications
The above results support the view that specific regulatory
elements, super-enhancers, are sensitive to the HD mutation.
Recent data indicate that selective promoters are also impaired in
the striatum of HD mice and patients. Investigating H3K4me3, a
mark of active promoters, down-regulated genes in the striatum
and cortex of HD R6/2 mice were found to preferentially
associate with broad promoters, regulating genes enriched in
biological processes linked to neuronal function (Vashishtha
et al., 2013). Moreover, H3K4me3 appeared decreased at down-
regulated genes in R6/2 vs. WT tissues (Figure 2). Thus, these
results show that specific broad promoter signature associates
with decreased expression of neuronal genes in the striatum
and cortex of HD mice. It is very likely that target genes of
broad promoters and super-enhancers in brain tissues overlap
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FIGURE 3 | Role of super-enhancers in gene down-regulation in HD. Super-enhancers, a category of large enhancers enriched in H3K27ac, regulate
transcription of neuronal identity genes in the striatum. In HD mouse striatum, H3K27ac and RNA polymerase II (RNAP II) are decreased at super-enhancers, which
likely contributes to reduced transcription of neuronal identity genes. TF, transcription factor.
and are enriched in neuronal identity genes. Moreover, in a
study using ChIPseq on embryonic stem cells (ESC) and neural
progenitor cells (NPC) expressing mutant Htt with various CAG
sizes, a correlation was reported between CAG-repeat-dependent
changes in gene expression and in H3K4me3 levels, particularly
in NSC (Biagioli et al., 2015). This raises the hypothesis that
mutant Htt might alter epigenetic regulation at early stage of
neuronal differentiation. Finally, H3K4me3 has been investigated
in the prefrontal cortex of HD patients using ChIPseq (Bai et al.,
2015; Dong et al., 2015). In contrast to mouse data, human
data indicate that epigenetic and transcriptional changes in HD
vs control tissues are poorly correlated (Bai et al., 2015; Dong
et al., 2015). However, in human experiments, sequencing depth
appears suboptimal, which may have resulted in underestimation
of H3K4me3 signals. Interestingly however, the study by Dong
et al. (2015) indicates that promoters differentially enriched in
H3K4me3 associate with genes involved in pathways or network
linked to neuronal activity and inflammation, suggesting that
transcriptional changes affecting inflammatory genes, in addition
to those affecting neuronal genes, involve epigenetic mechanisms
(Figure 2). The hypothesis that induction of inflammatory genes
in HD neuronal tissues associates with loss of identity of glial cells
would need to be investigated (Gabel et al., 2016).
Additional epigenetic modifications at regulatory regions
might also be impaired. Increased levels of H3K9me2, a
mark associated with heterochromatin, have been reported
in the striatum of HD patients and R6/2 mice, using
immunohistological analyses (Ryu et al., 2006). Whether
specific loci are more particularly sensitive to increased H3K9
methylation in HD models has yet to be investigated using
genome-wide approach. Moreover, the level of H3K27me3, a
repressive histone modification that can mark promoters and
enhancers, was modulated by CAG-repeat size in both ESC and
NPC (Seong et al., 2010; Biagioli et al., 2015). However, the
transcriptional consequences of this effect were unclear. Finally,
H2A ubiquitylation (H2Aub) was found increased at down-
regulated genes in HD R6/2 mice (Kim et al., 2008), and ChIP-
on-chip analysis of H2Aub changes in R6/2 striatum indicated
that histone changes were not restricted to dysregulated genes
(McFarland et al., 2012).
DNA methylation
Genome-wide analysis of DNA methylation was performed in
HD cell models (Ng et al., 2013). Changes in DNA methylation
in response to mutant Htt were observed at both promoter
proximal and distal regulatory regions. Interestingly, a large
fraction of the genes that changed in expression upon mutant
Htt expression displayed changes in DNA methylation, suggestive
of a causal relationship (Figure 2). DNA methylation was
also profiled using post-mortem cortex and liver from HD
patients (De Souza et al., 2016). The results revealed minimal
evidence of HD-associated DNA methylation. However, the HTT
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gene was methylated in a tissue-specific manner, which might
lead to tissue-specific regulation of HTT promoter activity.
Additionally, 5-hydroxymethylcytosine (5-hmC) and 7-methyl
guanine (7-MG) were globally reduced in brain tissues of HD
mouse models, including YAC128 mice (5-hmC study), R6/2
and CAG140 knockin mice (7-MG study) (Thomas et al.,
2013; Wang et al., 2013). While these studies further provide
evidence for altered DNA methylation in HD brain tissues,
transcriptional consequences of such impairments remains
elusive. Analysis of DNA methylation has also been used to
assess the epigenetic clock of HD patients (Horvath et al., 2016).
Horvath recently developed an epigenetic measure of tissue age,
so-called epigenetic age, estimated from DNA methylation levels
of 353 CpG sites (Horvath, 2013). The study using brain tissues
from HD patients showed accelerated epigenetic aging in HD
brain, particularly in cortical tissues. However, this was not
the case for striatal tissues, possibly due to excessive neuronal
loss (Horvath et al., 2016). While transcriptional significance of
accelerated aging in HD brain is unclear, the data might reveal
an age-dependent alteration of epigenetic regulation. Finally,
treatment of HD mice with the HDAC inhibitor HDACi 4b led
to transgenerational effects, possibly mediated by increased DNA
methylation at CpG sites associated with Kdm5d (Jia et al., 2015).
Thus, DNA methylation may be a therapeutic target for HD.
Mechanisms Involved in Altered
Epigenetic Regulation in HD
As mentioned above, altered histone acetylation in HD has been
proposed to result from decreased activity of the HAT CBP, due
to CBP recruitment into aggregates of mutant Htt, CBP depletion
in neurons expressing mutant Htt and/or through an aberrant
interaction of CBP with soluble mutant Htt (Steffan et al., 2000;
Nucifora et al., 2001; Jiang et al., 2006; Seredenina and Luthi-
Carter, 2012; Glajch and Sadri-Vakili, 2015) (Figure 4). The effect
appears specific to CBP since CBP-related HAT p300 was unable
to rescue cell toxicity in overexpression assays (Nucifora et al.,
2001). However, although studies manipulating CBP levels in HD
models support a role for CBP in pathogenesis (Steffan et al.,
2000; Klevytska et al., 2010), including cognitive deficits (Giralt
et al., 2012), it is still unclear whether altered CBP underlies HD
neuronal transcriptional signature.
The activity of additional chromatin modulators was also
found affected by Htt and/or mutant Htt. Htt was associated with
polycomb repressive complex 2 (PRC2) in cell nucleus, which
facilitated stimulation of PRC2 activity (Figure 4). Noticeably,
CAG-expanded Htt further enhanced PRC2 activity in cell
models (Seong et al., 2010). However, although H3K27me3
ChIPseq analyses revealed that Htt null mutation in ESC
globally decreased H3K27me3, a result consistent with Htt-
mediated stimulation of PRC2, the trend was opposite in NPC,
suggesting that Htt may also be implicated in the process
of H3K27me3 removal, and these different roles for Htt on
H3K27me3 regulation may depend on cell differentiation state
(Biagioli et al., 2015). Thus, the role of mutant Htt on genome-
wide regulation of H3K27me3 needs to be further investigated,
particularly in mature neurons. It is especially important to
specify this issue since PRC2 deficiency in adult neurons leads
to molecular, electrophysiological and behavioral phenotypes
reminiscent to those seen in HD mice (von Schimmelmann et al.,
2016). In fact, inactivation of PRC2 in striatal neurons resulted
in re-expression of transcription factors involved in neuronal
differentiation and in down-regulation of striatal identity genes,
suggesting that transcriptional signatures resulting from PRC2
inactivation and from the expression of mutant Htt in the
striatum share similarities (von Schimmelmann et al., 2016).
Additional enzymes modulating histone methylation
were also deregulated in HD models. ESET/SETB1, a H3K9
methyltransferase, was increased in the striatum and cortex
of HD R6/2 mice due to SP1/SP3-mediated transcriptional
activation, which resulted in increased histone H3K9 methylation
(Ryu et al., 2006) (Figure 4). Moreover, KDM5C/JARID1C, an
enzyme involved in demethylation of H3K4me3, was up-
regulated in the striatum and cortex of HD R6/2 mice and
proposed to contribute to decreased H3K4me3 in HD brain
tissues (Ng et al., 2013; Vashishtha et al., 2013) (Figure 4).
Other studies further suggest that Htt and/or mutant Htt affect
chromatin structure through modulation of the activity of
enzymes regulating histone methylation, including H3K9 and
H3K4 methylation (Ooi and Wood, 2007; Lee et al., 2013; Dietz
et al., 2015).
As already mentioned, transcription factors also contribute
to remodel the chromatin through the recruitment of histone
modifying enzymes, including enzymes involved in histone
acetylation and methylation. For instance, following binding
to their cognate DNA response element, several transcription
factors can interact with CBP in a stimulus-dependent manner,
thereby increasing CBP concentration and histone acetylation
at selective gene regulatory elements (e.g., enhancers and/or
promoters) (Sterner and Berger, 2000). Thus, impaired level or
activity of transcription factors in HD may also affect epigenetic
regulations. Many transcription factors, including REST, SP1,
TAF130, p53, were found deregulated in cells expressing the
HD mutation, due to aberrant interaction with mutant Htt or
altered transcriptional regulations (Nucifora et al., 2001; Bae
et al., 2005; Ravache et al., 2010; Zuccato et al., 2010; Moumne
et al., 2013; Langfelder et al., 2016) (Figure 3). It is tempting to
speculate that some of these factors, particularly those regulating
neuronal differentiation or maintenance of neuronal fate (this is
for instance the case of REST), might contribute to HD epigenetic
and transcriptional alterations.
Additionally, the ability of transcription factors to interact
with chromatin-modifying enzymes depends in some cases on
the activation of specific signaling pathways, which permits to
optimize the coupling between epigenetic and transcriptional
responses after stimulation. This is the case for CREB, which
needs to be phosphorylated in response to activation of cAMP
signaling pathway, to bind and recruit CBP on chromatin
(Cardinaux et al., 2000). The Ras/MAPK/MSK1 signaling
pathway is another pathway, where transcriptional and epigenetic
responses are coordinated through phosphorylation events
targeting transcription factors and histones (e.g., ELK1 and
H3 at serine 10, respectively) (Brami-Cherrier et al., 2009;
Bahrami and Drablos, 2016). These pathways, which control
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FIGURE 4 | Additional mechanisms involved in gene down-regulation in HD. Mutant HTT (mHTT) leads to the modulation of the activity of chromatin
modifiers/complexes (e.g., CBP, ESET, KDM5C, PRC2) and transcriptional regulators (e.g., REST). (A) The HAT CBP is sequestrated in mHTT aggregates and/or
interacts with soluble mHTT, which reduces its activity, leading to reduction of histone acetylation. (B) Increased levels/activities of the H3K4me3 demethylase
KDM5C, of the methyltransferase ESET and of polycomb repressive complex PRC2 lead to increased histone methylation. (C) HTT interacts with REST, limiting its
availability in the nucleus. This interaction is impaired with mHTT, leading to increased binding of REST to RE1 elements and down-regulation of RE1-regulated
genes. ESET, ERG-Associated Protein with SET Domain; HTT, Huntingtin; KDM5C, Lysine Demethylase 5C; PRC2, polycomb repressive complex 2; REST, RE1
Silencing Transcription Factor.
the dynamics of IEGs expression such as Fos, Egr1, and
Arc, play a key role in the regulation of neuronal activity,
including plasticity and excitability (Besnard et al., 2011; West
and Greenberg, 2011; Lopez-Atalaya and Barco, 2014). Several
studies suggest that these pathways are impaired in HD striatum,
raising the hypothesis that the coupling between epigenetic
and transcriptional mechanisms regulating neuronal activity is
altered in HD (Besnard et al., 2011; Langfelder et al., 2016), which
might contribute to altered epigenetic regulations (Chawla et al.,
2003).
Despite these hypotheses, it remains unclear how mutant Htt
leads to selective alteration of the chromatin associated with
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TABLE 1 | Examples of histone deacetylase (HDACi)-alternative epigenetic therapies.
Drug family Target Molecules Mechanisms and effects Reference
HAT activators p300/CBP N-(4-chloro-3-trifluoromethyl-phenyl)-2-
ethoxy-6-pentadecyl-ben-zamide
(CTPB)
CTPB leads to the neurite growth of a PD cell model,
and protects them from cell death induced by the
neurotoxin 6-hydroxydopamine.
Hegarty et al., 2016
p300/CBP CSP-TTK21 CSP-TTK21 promotes differentiation and maturation of
young adult hippocampal neurons and improves
long-term retention of a spatial memory.
Chatterjee et al.,
2013
HAT inhibitors p300 C646 C646 reduces amount of Tau and neurotoxicity in
culture rat neurons. C646 enhances fear extinction
memory and synaptic plasticity.
Min et al., 2010
Histone
methyltransferase
inhibitors
EZH2 3- deazaneplanocin A (DZNep) DZNep reactivates silenced genes in cancer cells and
developmental genes that are not silenced by DNA
methylation. DZNep inhibits H3K27me3 and
H4K20me3.
Miranda et al.,
2009
DNA
methyltransferase
inhibitors
DNMT1&3 Nucleoside analog:
5-fluoro-2’-deoxycytidine (FdCyd)
FdCyd has neuroprotective effects against mutant
Htt-induced toxicity in primary cortical neurons in cell
viability and neurite degeneration assays.
Pan et al., 2016
DNMT1&3 Non-nucleoside inhibitor : RG108 RG108 is a DNMT active site inhibitor. RG108 blocks
the increase in 5-methycytosine and prevents cell death
in a mouse model of motor neuron disease model.
Chestnut et al.,
2011
DNA
methyltransferase
activators
DNMT PARP Loss of nucleolar PARP-1 results in DNA
methyltransferase activation. This may impact on
ribosomal DNA silencing observed in AD.
Zeng et al., 2016
DNMT1 Epstein-Barr virus latent membrane
protein 1 (LMP1)
LMP1 directly induces the dnmt1 promoter activity
through its COOH-terminal activation region-2 YYD
domain.
Tsai et al., 2006;
Li J. et al., 2016
CBP, CREB-binding protein; EZH2, Enhancer of Zeste Homolog 2; DNMT, DNA MethylTransferase; HAT, Histone AcetylTransferase.
neuronal identity genes. The underlying mechanism may be
the addition of direct effects of mutant Htt on the chromatin
and transcription regulators described above (e.g., CBP, PRC2,
ESET/SETB1, KDM5C/JARID1C, REST, SP1, CREB, TAF130,
p53). Alternatively, it may be the result of an indirect mechanism
caused by mutant Htt on neuronal homeostasis and activity that
is yet to be identified.
EMERGING PICTURE AND
PERSPECTIVES
Here, we reviewed the current understanding of the role of
neuroepigenetics in HD, in an attempt to uncover the significance
of epigenetic changes in HD brain, a prerequisite to the rational
design of epigenetic therapies.
Three main questions underlie the review: (1) What are
epigenetic changes in HD? (2) What is the consequence
of epigenetic changes in HD, particularly on transcriptional
regulation? (3) What mechanism(s) cause(s) epigenetic changes
in HD? Although, we still lack complete answers to any of these
questions, an emerging picture arises, supporting the view that
maintenance and/or establishment of neuron-specific chromatin
identity is altered in HD, which leads to down-regulation of
neuronal identity genes. This suggests that mutant Htt might
interfere with neuronal differentiation, in agreement with recent
studies (Molero et al., 2016). To investigate this hypothesis, it will
be crucial to assess HD epigenome and transcriptome across time,
including developmental stages. If altered epigenetic regulation
in HD brain results in down-regulation of neuronal identity
genes, it is very likely to disturb neuronal activity, including
synaptic plasticity and neuronal excitability, controlling learning
and memory processes. This will need to be investigated. The
issue of tissue-/cell-specificity of epigenetic alterations in HD
also remains to be investigated. It is unclear whether the HD
mutation induces similar epigenetic changes between cell types
(e.g., neurons vs. glial cells) or between different tissues (e.g.,
striatum vs. cortex, hippocampus or cerebellum, neuronal tissue
vs. non-neuronal tissue). It will also be crucial to investigate
the timing of establishment of super-enhancer signatures relative
to transcriptional changes to specify the relationship between
epigenetic and transcriptional changes in HD brain tissues.
Addressing these questions will certainly provide insights into
the mechanism causing epigenetic and transcriptional changes in
HD, which may be a key to the identification of new therapeutic
targets.
Comprehensive analysis of the HD epigenome using various
HD models and genome-wide techniques, including techniques
that permit to investigate epigenomes at cell type-specific or
single-cell scale and in 3D (using chromosome conformation
capture- (3C)-based methods) is necessary to address these
questions. Another challenge will be to develop bioinformatics
methods to analyze the data and extract meaning. This may
require the development of approaches that reduce complexity,
such as network-based methods (Langfelder and Horvath, 2008;
Parmentier et al., 2013).
Epigenetic therapies to treat neurodegenerative diseases have
been first considered for HD, when Steffan et al. (2000) showed
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that HDAC inhibitors improve the phenotype of HD flies.
In fact, preclinical studies to evaluate the effect of HDAC
inhibitors in HD have inspired other neurodegenerative diseases,
including additional trinucleotide repeat (TNR) diseases (for
review see Evans-Galea et al., 2013) PD, Alzheimer disease
(AD), and amyotrophic lateral sclerosis (ALS) (Xu et al.,
2011; Lazo-Gomez et al., 2013; Sharma and Taliyan, 2015a).
Beneficial effects have been observed in preclinical models
for these different diseases, though the effects of HDAC
inhibitors appear partial and underlying mechanisms are
unclear (Benito et al., 2015; Harrison et al., 2015). In the
specific case of TNR diseases, HDAC inhibitors may affect
disease progression through two independent mechanisms:
(1) through a general effect on gene expression program,
(2) through modulation of the stability of TNRs, which
are subject to epigenetic regulations (Goula et al., 2012;
Evans-Galea et al., 2013). To overcome limitations associated
with the use of HDCAi, including the lack of specificity
and toxicity, HDACi-alternative epigenetic therapies are
currently being developed that are based on HAT activators,
histone methyltransferase inhibitors and DNMT modulators
(Table 1).
Epigenomic studies on HD models might benefit from studies
in other neurodegenerative diseases and reciprocally. Indeed,
the similarity of epigenomic and transcriptomic signatures
between HD and AD models (e.g., neuronal and inflammation
signatures) is intriguing and might suggest that common
epigenetic mechanisms to several neurodegenerative diseases
might operate (Gjoneska et al., 2015).
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